Range Impact (RNGE) 10-Q/A 18 Nov 15 2016 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2015	Nov. 13, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stevia First Corp.
Entity Central Index Key	1,438,943
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	STVF
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	The purpose of this Amendment No. 1 to Stevia First Corp.'s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, filed with the Securities and Exchange Commission on November 16, 2015 (the "Form 10-Q"), is solely to furnish Exhibit 101 to the Form 10-Q. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016
Entity Common Stock, Shares Outstanding		78,867,074

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Current Assets
Cash	$ 692,679	$ 389,730
Accounts receivable, net	42,927	61,595
Inventory	9,432	8,478
Prepaid expense	2,500	2,500
Total Assets	747,538	462,303
Current Liabilities
Accounts payable and accrued liabilities	183,534	134,007
Accounts payable - related party	6,900	1,000
Derivative liability	788,492	1,406,596
Total liabilities	978,926	1,541,603
Stockholders' Deficit
Common stock, par value $0.001 per share; 525,000,000 shares authorized; 78,603,917 and 72,968,915 shares issued and outstanding, respectively	78,604	72,969
Additional paid-in-capital	11,345,322	11,222,965
Accumulated deficit	(11,655,314)	(12,375,234)
Total stockholders’ deficit	(231,388)	(1,079,300)
Total liabilities and stockholders’ deficit	$ 747,538	$ 462,303

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Mar. 31, 2015
Balance Sheet [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	525,000,000	525,000,000
Common stock, shares issued	78,603,917	72,968,915
Common stock, shares outstanding	78,603,917	72,968,915

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement
Revenues	$ 51,697	$ 86,695	$ 113,612	$ 128,136
Cost of goods sold	41,199	22,106	65,232	33,981
Gross profit	10,498	64,589	48,380	94,155
Operating Expenses:
General and administrative	556,945	933,060	1,298,541	1,499,726
Rent and other related party costs	4,900	9,900	15,800	30,217
Research and development	143,133	207,663	326,658	453,643
Total operating expenses	704,978	1,150,623	1,640,999	1,983,586
Loss from operations	(694,480)	(1,086,034)	(1,592,619)	(1,889,431)
Other income (expenses)
Change in fair value of derivative liability	1,198,954	644,107	2,312,755	792,364
Cost to induce exercise of warrants		(961,767)		(961,767)
Interest expense	(148)	(4,055)	(216)	(4,712)
Total other income (expense), net	1,198,806	(321,715)	2,312,539	(174,115)
Net income (loss)	$ 504,326	$ (1,407,749)	$ 719,920	$ (2,063,546)
Net income (loss) per common share – Basic	$ 0.01	$ (0.02)	$ 0.01	$ (0.03)
Net income (loss) per common share – Diluted	$ 0.01	$ (0.02)	$ 0.01	$ (0.03)
Weighted average number of common shares - basic	78,571,200	68,630,355	77,223,343	67,356,536
Weighted average number of common shares - diluted	78,571,200	68,630,355	77,223,343	67,356,536

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS’ DEFICIT - 6 months ended Sep. 30, 2015 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, amount at Mar. 31, 2015	$ 72,969	$ 11,222,965	$ (12,375,234)	$ (1,079,300)
Balance, shares at Mar. 31, 2015	72,968,915
Issuance of common stock and warrants, net of derivative liability, amount	$ 5,000	(408,077)		(403,077)
Issuance of common stock and warrants, net of derivative liability, shares	5,000,002
Fair value of vested common stock issued to employees and director, amount		93,468		93,468
Fair value of common stock issued for services, amount	$ 635	175,365		176,000
Fair value of common stock issued for services, shares	635,000
Fair value of vested stock options		149,556		149,556
Fair value of vested warrants		112,045		112,045
Net income			719,920	719,920
Balance, amount at Sep. 30, 2015	$ 78,604	$ 11,345,322	$ (11,655,314)	$ (231,388)
Balance, shares at Sep. 30, 2015	78,603,917

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net income (loss)	$ (1,407,749)	$ 719,920	$ (2,063,546)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Fair value of vested stock options		149,556	121,721
Fair value of vested common stock issued to employees and director		93,468	203,680
Change in fair value of derivative liability	(644,107)	(2,312,755)	(792,364)
Fair value of common stock issued for services		176,000	144,100
Fair value of vested warrants		112,045	278,711
Cost to induce exercise of warrants	961,767		961,767
Changes in operating assets and liabilities:
Accounts receivable		18,668	99
Inventory		(954)	(19,417)
Prepaid expense			(10,827)
Advance payment on related party lease			10,413
Accounts payable and accrued liabilities		49,527	73,543
Accounts payable - related party		5,900	(15,100)
Net cash used in operating activities		(988,625)	(1,107,220)
Investing activities
Acquisition of cash upon acquisition			10,505
Net cash provided by investing activities			10,505
Financing activities
Proceeds from exercise of warrants			1,470,489
Proceeds from exercise of options			$ 5,000
Proceeds from sale of common stock, net		1,291,574
Net cash provided by financing activities		1,291,574	$ 1,475,489
Net increase (decrease) in cash		302,949	378,774
Cash and cash equivalent - beginning of period		389,730	1,403,403
Cash and cash equivalent - end of period	$ 1,782,177	692,679	1,782,177
Cash paid during the period for:
Interest		$ 216	$ 4,055
Income taxes
Non-cash activities:
Fair value of warrants issued with common stock recorded as derivative liability		$ 1,694,651
Acquisition of accounts receivable upon acquisition			$ 39,495
Issuance of unvested common stock to employee			458,000
Extinguishment of derivative liability			$ 269,368

BUSINESS AND BASIS OF OPERATION

BUSINESS AND BASIS OF OPERATIONS	6 Months Ended
	Sep. 30, 2015
BUSINESS AND BASIS OF OPERATIONS [Abstract]
BUSINESS AND BASIS OF OPERATIONS	1. BUSINESS AND BASIS OF OPERATIONS Stevia First Corp. (the “Company”, “we”, “us” or “our”) was incorporated under the laws of the State of Nevada on June 29, 2007. In February 2012, we substantially changed our management team, added other key personnel, and began leasing laboratory and office space and land in California and since then we have been pursuing our new business as an agricultural biotechnology company engaged primarily in developing novel methods and technologies for industrial production of stevia, using such methods and technologies to develop, obtain approval for and commercialize one or more stevia extract products, and exploring and commercializing additional research applications for such methods and technologies. Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and utilized cash in operations since inception resulting in stockholders’ deficit of $ 231,388 as of September 30, 2015, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2015 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the 6 months after September 30, 2015. We will require additional financing to fund our planned long-term operations, including our commitment under our distribution and license agreements with Qualipride International (“Qualipride”) (See Note 8) . These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment. Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and six months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”) . Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2015 was derived from the audited financial statements as of and for the year ended March 31, 2015 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 25, 2015. These financial statements should be read in conjunction with that report.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At September 30, 2015, and March 31, 2015, the allowance for doubtful accounts and returns and discounts was approximately $ 17,500 and $ 2,900 , respectively. Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820), formerly SFAS No. 157 “Fair Value Measurements”. ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The following table presents certain liabilities of the Company that are required to be measured and recorded at fair value on the Company’s balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2015 and March 31, 2015: September 30, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $ March 31, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $ The carrying value of cash, accounts receivable and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2015 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Basic and Diluted Loss Per Share The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. As of September 30, 2015 potentially dilutive securities include options to acquire 8, 991,667 shares of common stock and warrants to acquire 25,027, 1 34 shares of common stock. At September 30, 2014 potentially dilutive securities include options to acquire 5,525,000 shares of common stock and warrants to acquire 12,127,129 shares of common stock. The basic and fully diluted shares for the three and six months ended September 30, 201 5 and September 30, 2014 are the same because the inclusion of the potential shares would have had an anti-dilutive effect and there were no instruments that would result in issuance of additional shares using the treasury stock method . Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. . Recent Accounting Pronouncements In November 2014, the FASB issued Accounting Standards Update No. 2014-16 (ASU 2014-16), Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in this ASU do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. The ASU applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 . Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2014-16 on the Company's results of operations or financial condition. In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2014-15 on the Company's results of operations or financial condition. In May 2014, FASB issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers . ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principles-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on the Company’s ongoing financial reporting. In April 2014, the FASB issued Accounting Standards Update No. 2014-08 (“ASU 2014-08”), “ Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ” ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	6 Months Ended
	Sep. 30, 2015
DERIVATIVE LIABILITY [Abstract]
DERIVATIVE LIABILITY	3. DERIVATIVE LIABILITY In June 2008, the FASB issued authoritative guidance on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock. Under the authoritative guidance, effective January 1, 2009, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The warrants issued to purchasers and placement agent in June 2013 and September 2014, and the warrants issued to investors in May 2015, do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future or have other variable provisions. The Company was required to include the reset provisions in order to protect the holders of the warrants from the potential dilution associated with future financings, and a fundamental transaction provision, which require a revaluation of the liabilities. In accordance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. As of March 31, 2015, at applicable date of issuance and September 30, 2015, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants: March 31, 2015 Upon Issuance September 30, 2015 Exercise Price $ 0.34 - 0.45 $ 0.35 - 0.45 $ 0.30 - 0.45 Stock Price $ $ $ Risk-free interest rate 0.41 - 1.25 % 0.17 - 1.59 % 0.08 - 1.31 % Expected volatility % 76.26 - 107.51 % % Expected life (in years) 2.5 - 4.5 years 0.75 - 5.0 years 0.36 - 4.7 years Expected dividend yield Fair Value: $ $ $ The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration dates of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. As of March 31, 2015, the Company’s derivative liabilities had a balance of $ 1,406,596 . In May 2015, we recognized additional derivative liabilities of $ 1,694,651 related to the warrants issued in conjunction with the sale of the Company’s common stock (described in Note 4). For the six months ended September 30, 2015, the Company recorded a reduction in fair value of the derivative liability of $ 2,312,755 . As of September 30, 2015, the aggregate fair value of the derivative liabilities was $ 788,492 .

EQUITY

EQUITY	6 Months Ended
	Sep. 30, 2015
EQUITY [Abstract]
EQUITY	4. EQUITY Equity Financing In May 20 15, the Company entered into a Securities Purchase A greement with seven purchasers for the sale of an of aggregate of 5,000,002 shares of the Company’s common stock (collectively, the “Shares”) , and warrants to purchase an aggregate of 12,500,005 shares of the Company’s common stock for total gross proceeds of $ 1,500,000 , or a sales price of $ 0.30 per share (the “Offering”). The Offering closed on May 11, 2015. The Company incurred $ 208,426 direct costs, fees and expenses in connection with the Offering, resulting in net cash proceeds to the Company of $ 1,291,574 . The warrants to purchase an aggregate of 12,500,005 issued to the purchasers in the Offering were issued in three tranches: Series A Warrants to purchase up to an aggregate of 5,000,002 shares of the Company’s common stock, with exercise price of $ 0.45 per share, and a term of 5 years; Series B Warrants to purchase up to an aggregate of 5,000,002 shares of the Company’s common stock, with exercise price of $ 0.35 per share, and a term of 9 months; and Series C Warrants to purchase up to an aggregate of 2,500,001 shares of the Company’s common stock , with exercise price of $ 0.40 per share, and a term of 1 year; all of which are exercisable immediately (the Series A Warrants, the Series B Warrants and the Series C Warrants , collectively, the “Warrants”). The Company also issued warrants to purchase up to 400,000 shares of the Company’s common stock (the “Placement Agent Warrants”) to H.C. Wainwright & Co., LLC as placement agent to the Offering. The Placement Agent Warrants have an exercise price of $ 0.375 per share , a term of 5 years, and are exercisable immediately. The exercise price of the Series A Warrants granted to the purchasers of the Offering includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $ 0.20 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and the Placement Agent Warrants are subject to provision for certain fundamental transactions. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that the exercise prices of the Warrants and the Placement Agent Warrants were not fixed amounts because they are subject to fluctuation based on the occurrence of future offerings or events, and certain fundamental transactions. As a result, the Company determined that the Warrants and the Placement Agent Warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as derivative liabilities upon issuance. The Company determined the aggregate initial fair value of the Warrants and the Placement Agent Warrants in the Offering to be $ 1,694,651 at issuance valued using a probability weighted average Black-Scholes-Merton pricing model. For financial statement purposes, the amount of the derivative liability created from the issuance of the Warrants and the Placement Agent Warrants of $ 1,694,651 has been offset to the net cash proceeds received of $ 1,291,574 , resulting in a net reduction of additional paid-in capital of $ 408,077 from the sale of the Shares of common stock and Warrants. Common stock issued to employees for services with vesting terms The Company has issued shares of common stock to employees and directors that vest over time. These shares of common stock were valued based upon the market price of the Company’s common stock at the dates of grant and determined the aggregate fair values to be of approximately $ 683,000 . The allocable portion of the aggregate fair values of these shares of commo n stock that vested during the six months ended September 30, 2015 and 2014 amounted to $ 93,468 and $ 203,680 , respectively, and were recognized as expense in the accompanying statements of operations during the periods then ended. As of September 30, 2015, approximately $ 170,000 of these awards remains unvested and will be amortized as compensation costs in future years. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement. The following table summarizes restricted common stock activity: Number of Shares Non-vested shares, March 31, 2015 Granted - Vested Forfeited - Non-vested shares, September 30, 2015 Common stock issued to consultants for services In May 2015, pursuant to the terms of certain consulting agreement, the Company issued an aggregate of 325,000 shares of the Company’s common stock to two consultants as payment for ser vices and recorded an expense of $ 115,000 based on the fair value of the Company’s common stock at the issuance dates. In July 2015, we issued a total of 310,000 shares of our common stock to two consultants in exchange for services and recorded an expense of $ 61,000 . These shares were issued outside of the 2012 Stock Incentive Plan.

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Sep. 30, 2015
STOCK OPTIONS [Abstract]
STOCK OPTIONS	5. STOCK OPTIONS Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award. A summary of the Company’s stock option activity for the six months ended September 30, 2015 is presented below: Shares Weighted Average Exercise Price Balance at March 31, 2015 $ Granted Exercised - - Cancelled Balance outstanding at September 30, 2015 $ Balance exercisable at September 30, 2015 $ At September 30, 2015, options to purchase common shares were outstanding as follows: Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, September 30, 2015 $ $ $ 0.20 - 0.27 $ 0.20 - 0.27 $ 0.31 - 0.38 $ 0.31 - 0.38 $ 0.40 - 0.47 $ 0.40 - 0.47 $ $ Options Exercisable, September 30, 2015 $ $ $ 0.20 - 0.27 $ 0.20 - 0.27 $ 0.31 - 0.38 $ 0.31 - 0.38 $ 0.40 - 0.47 $ 0.40 - 0.47 $ $ During the six months ended September 30, 2015, the Company granted to employees options to purchase an aggregate of 1,375,000 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from 0 months to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 7 6.26 %, (ii) discount rate of 2.19 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $ 233,000 . During the six months ended September 30, 2015, the Company also granted to four consultants options to purchase an aggregate of 1,300,000 shares of the Company’s common stock that expire three years from date of grant and vested upon grant. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 109.32 %, (ii) discount rate of 1.01 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $ 127,000 . During the six months ended September 30, 2015 and 2014, we expensed total stock-based compensation related to vesting stock options of $ 149,556 and $ 121,721 , respectively, and the remaining unamortized cost of the outstanding stock options at September 30, 2015 was approximately $ 300,000 . This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded. The intrinsic values of all outstanding and exercisable stock options at September 30, 2015 were $ 0 and $0 , respectively, and $320,500 and $318,500 , respectively, at September 30, 2014.

WARRANTS

WARRANTS	6 Months Ended
	Sep. 30, 2015
WARRANTS [Abstract]
WARRANTS	6. WARRANTS At September 30, 2015, warrants to purchase common shares were outstanding as follows: Shares Weighted Average Exercise Price Balance at March 31, 2015 $ Granted Exercised - - Cancelled - $ - Balance outstanding and exercisable at September 30, 2015 $ Warrants issued in equity financing In May 2015, the Company granted 5,000,002 Series A warrants, 5,000,002 Series B warrants and 2,500,001 Series C warrants in connection with an offering of the Company’s common stock for cash. Each Series A Warrant has an exercise price of $ 0.45 per share, was immediately exercisable, and expires on the five year anniversary of the date of issuance. Each Series B Warrant has an exercise price of $ 0.35 per share, was immediately exercisable, and will expire on the nine month anniversary of the date of issuance. Each Series C Warrant has an exercise price of $ 0.40 per share, was immediately exercisable, and will expire on the one year anniversary of the date of issuance. T he Company also issued Placement Agent Warrants to purchase up to 400,000 shares of the Company’s common stock to H.C. Wainwright. The Placement Agent Warrants have an exercise price of $ 0.375 per share, a term of 5 years, and are exercisable immediately. The exercise price of the Series A Warrants granted to the purchasers of the Offering includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $0.20 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and to the placement agent are subject to provision for certain fundamental transactions. In consideration of applicable guidance, the Company has determined that none of the warrants are considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterizes the fair value of these warrants as derivative liabilities (See Note 3). Warrants issued to employees On August 25, 2014, we entered into employment agreements with two new employees, pursuant to which, these employees became entitled to receive warrants to purchase an aggregate of 4,400,000 shares of the Company’s common stock as discussed in Note 8 . These warrants have an exercise price of $ 0.30 , and a term of ten years from issue date. Vesting terms of these warrants are as follows: (i) warrants to purchase 800,000 shares of common stock vested immediately at their grant date with a fair value of $ 201,680 , which w as recorded as an expense during the year ended March 31, 2015, (ii) warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years with a fair value of $ 504,204 upon grant date , which is being amortized over their vesting terms, of which $ 112,045 were recorded as an expense during the six months ended September 30, 2015, and (iii) warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement (See Note 8). T he remaining unamortized cost of the outstanding warrants at September 30, 2015 was approximately $ 1 61,000 . The aggregate intrinsic value of all of the outstanding and exercisable warrants at September 30, 2015 and 2014 was approximately $0 and $ 104,000 , respectively.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	6 Months Ended
	Sep. 30, 2015
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS [Abstract]
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	7. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS Related party lease obligations On April 23, 2012, the Company entered into a lease agreement (the “Carlson Lease”) with One World Ranches, LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California. The Carlson Lease began on May 1, 2012 and expires on May 1, 2017 , and the Company’s rent payments thereunder are $ 2,300 per month. The Company has paid $ 1,500 as a refundable security deposit under the Carlson Lease. On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease an apartment located at 33-800 Clark Avenue, Yuba City, California. The Company uses this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and the Company’s rent payment is $ 1,000 per month. On August 22, 2012, the Company paid $ 1,000 as a refundable security deposit under the Sacramento Lease. Aggregate payments under the above leases for the six months ended September 30, 2015 and 2014 were $ 15,8 00 and $ 30,950 , respectively.

DISTRIBUTION AND LICENSE AGREEM

DISTRIBUTION AND LICENSE AGREEMENTS	6 Months Ended
	Sep. 30, 2015
DISTRIBUTION AND LICENSE AGREEMENTS [Abstract]
DISTRIBUTION AND LICENSE AGREEMENTS	8. DISTRIBUTION AND LICENSE AGREEMENTS On August 25, 2014, as amended on August 12, 2015, we entered into a distribution agreement with Qualipride International (“Qualipride”), a stevia supplier located and organized in the People’s Republic of China, under which we became the exclusive worldwide distributor of Qualipride’s stevia products and acquired Qualipride’s customer list. Pursuant to the distribution agreement, Qualipride will supply products to the Company at its cost, plus up to 2 % for handling costs and up to a 5 % sales commission. We are obligated to hire and train sales personnel or appoint representatives to introduce, promote, market and sell Qualipride’s products worldwide. In addition, we must file a “generally recognized as safe” notice with the U.S. Food and Drug Administration for one or more of Qualipride’s stevia products prior to August 14, 2016. The Company will account for such costs as such sales are made, or such other direct costs are incurred. Concurrently, we also entered into a license agreement with Qualipride, Mr. Dong Yuejin and Mr. Guo Yuxiao, in which we obtained an exclusive license outside China to use Qualipride’s proprietary methods and designs for stevia extraction and purification facilities. Pursuant to the license agreement, as amended on August 12, 2015, we must obtain financing of at least $ 2.55 million prior to August 14, 2016 or the license granted to us will terminate, which funds we intend would be used to build a stevia extraction and purification facility in California. The license agreement also requires us to make payments to Qualipride of up to $ 700,000 upon securing required financing and achievement of certain other milestones, in addition to royalty payments of between $ 1.00 and $ 2.00 for each kilogram of certain specified stevia extracts produced at a California stevia production facility that is designed using the methods subject to the license grant. The Company will account for the costs of such license and obligation once such financing has been received. During the six months ended September 30, 2015, the Company did not receive any financing pursuant to the terms of the license agreement. Concurrently with such arrangements, we also entered into employment agreements with Mr. Dong and Mr. Guo. Under the employment agreements, in addition to their base salaries, Mr. Dong and Mr. Guo are entitled to receive an aggregate of 2,400,000 restricted shares of our common stock and warrants to purchase up to an aggregate of 4,400,000 shares of our common stock. An aggregate of 400,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 800,000 shares of our common stock vested immediately upon issuance with an aggregate fair value of $321,680 , which was recorded as an expense during the year ended March 31, 2015 . An aggregate of 1,000,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 2,000,000 shares of our common stock have vesting terms ranging from one to three years (see Note 4 for a discussion of the vesting of the common stock and Note 6 for a discussion of the vesting of the warrants). An aggregate of 1,000,000 shares of our restricted common stock will be issued and warrants to purchase up to an aggregate of 1,600,000 shares of our common stock will vest once we achieve certain milestones, including reaching more than $ 5 million in annual revenue and the planned California stevia extraction and purification facility becoming operational and meeting certain technical performance specifications . The Company will account for the costs of the 1,000,000 shares of common stock and warrants to purchase up to an aggregate of 1,600,000 shares of common stock, at the time their issuance becomes probable.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Sep. 30, 2015
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS In October 2015, we issued a total of 263,157 shares of our common stock to one consultant in exchange for services valued at $ 50,000 .

BUSINESS AND BASIS OF OPERATI16

BUSINESS AND BASIS OF OPERATIONS (Policies)	6 Months Ended
	Sep. 30, 2015
BUSINESS AND BASIS OF OPERATIONS [Abstract]
Going Concern	Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and utilized cash in operations since inception resulting in stockholders’ deficit of $ 231,388 as of September 30, 2015, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2015 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the 6 months after September 30, 2015. We will require additional financing to fund our planned long-term operations, including our commitment under our distribution and license agreements with Qualipride International (“Qualipride”) (See Note 8) . These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.
Basis of Presentation of Unaudited Condensed Financial Information	Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and six months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”) . Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2015 was derived from the audited financial statements as of and for the year ended March 31, 2015 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 25, 2015. These financial statements should be read in conjunction with that report.

SUMMARY OF SIGNIFICANT ACCOUN17

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities.
Accounts Receivable	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At September 30, 2015, and March 31, 2015, the allowance for doubtful accounts and returns and discounts was approximately $ 17,500 and $ 2,900 , respectively.
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820), formerly SFAS No. 157 “Fair Value Measurements”. ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The following table presents certain liabilities of the Company that are required to be measured and recorded at fair value on the Company’s balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2015 and March 31, 2015: September 30, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $ March 31, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $ The carrying value of cash, accounts receivable and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2015 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. As of September 30, 2015 potentially dilutive securities include options to acquire 8, 991,667 shares of common stock and warrants to acquire 25,027, 1 34 shares of common stock. At September 30, 2014 potentially dilutive securities include options to acquire 5,525,000 shares of common stock and warrants to acquire 12,127,129 shares of common stock. The basic and fully diluted shares for the three and six months ended September 30, 201 5 and September 30, 2014 are the same because the inclusion of the potential shares would have had an anti-dilutive effect and there were no instruments that would result in issuance of additional shares using the treasury stock method .
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2014, the FASB issued Accounting Standards Update No. 2014-16 (ASU 2014-16), Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in this ASU do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. The ASU applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 . Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2014-16 on the Company's results of operations or financial condition. In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2014-15 on the Company's results of operations or financial condition. In May 2014, FASB issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers . ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principles-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on the Company’s ongoing financial reporting. In April 2014, the FASB issued Accounting Standards Update No. 2014-08 (“ASU 2014-08”), “ Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ” ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

SUMMARY OF SIGNIFICANT ACCOUN18

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Investments and Liabilities of Assets Measured at Fair Value on Recurring Basis	The following table presents certain liabilities of the Company that are required to be measured and recorded at fair value on the Company’s balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2015 and March 31, 2015: September 30, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $ March 31, 2015 Level 1 Level 2 Level 3 Total Fair value of Derivative Liability $ - $ $ - $

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	6 Months Ended
	Sep. 30, 2015
DERIVATIVE LIABILITY [Abstract]
Valuation Assumptions for Derivative Liabilities	As of March 31, 2015, at applicable date of issuance and September 30, 2015, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants: March 31, 2015 Upon Issuance September 30, 2015 Exercise Price $ 0.34 - 0.45 $ 0.35 - 0.45 $ 0.30 - 0.45 Stock Price $ $ $ Risk-free interest rate 0.41 - 1.25 % 0.17 - 1.59 % 0.08 - 1.31 % Expected volatility % 76.26 - 107.51 % % Expected life (in years) 2.5 - 4.5 years 0.75 - 5.0 years 0.36 - 4.7 years Expected dividend yield Fair Value: $ $ $

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Sep. 30, 2015
EQUITY [Abstract]
Schedule of Nonvested Restricted Common Stock Activity	The following table summarizes restricted common stock activity: Number of Shares Non-vested shares, March 31, 2015 Granted - Vested Forfeited - Non-vested shares, September 30, 2015

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Sep. 30, 2015
STOCK OPTIONS [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the six months ended September 30, 2015 is presented below: Shares Weighted Average Exercise Price Balance at March 31, 2015 $ Granted Exercised - - Cancelled Balance outstanding at September 30, 2015 $ Balance exercisable at September 30, 2015 $
Options to Purchase Common Shares	At September 30, 2015, options to purchase common shares were outstanding as follows: Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, September 30, 2015 $ $ $ 0.20 - 0.27 $ 0.20 - 0.27 $ 0.31 - 0.38 $ 0.31 - 0.38 $ 0.40 - 0.47 $ 0.40 - 0.47 $ $ Options Exercisable, September 30, 2015 $ $ $ 0.20 - 0.27 $ 0.20 - 0.27 $ 0.31 - 0.38 $ 0.31 - 0.38 $ 0.40 - 0.47 $ 0.40 - 0.47 $ $

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Sep. 30, 2015
WARRANTS [Abstract]
Summary of Warrant Activity	At September 30, 2015, warrants to purchase common shares were outstanding as follows: Shares Weighted Average Exercise Price Balance at March 31, 2015 $ Granted Exercised - - Cancelled - $ - Balance outstanding and exercisable at September 30, 2015 $

BUSINESS AND BASIS OF OPERATI23

BUSINESS AND BASIS OF OPERATIONS (Details) - USD ($)	6 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
BUSINESS AND BASIS OF OPERATIONS [Abstract]
Stockholders' equity (deficit)	$ (231,388)	$ (1,079,300)
Liquidity disclosure	We estimate that we will have sufficient funds to operate the business for the 6 months after September 30, 2015.

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Allowance for doubtful accounts receivable	$ 17,500		$ 2,900
Equity Option [Member]
Antidilutive securities excluded from computation of earnings per share	8,991,667	5,525,000
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share	25,027,134	12,127,129

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Investments and Liabilities Measured at Fair Value) (Details) - USD ($)	Sep. 30, 2015	May. 31, 2015	Mar. 31, 2015
Fair Value of Derivative Liability	$ 788,492	$ 1,694,651	$ 1,406,596
Fair Value, Inputs, Level 1 [Member]
Fair Value of Derivative Liability
Fair Value, Inputs, Level 2 [Member]
Fair Value of Derivative Liability	$ 788,492		$ 1,406,596
Fair Value, Inputs, Level 3 [Member]
Fair Value of Derivative Liability

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Net income (loss)	$ 504,326	$ (1,407,749)	$ 719,920	$ (2,063,546)
Weighted average shares outstanding (basic)	78,571,200	68,630,355	77,223,343	67,356,536
Weighted average shares outstanding (diluted)	78,571,200	68,630,355	77,223,343	67,356,536
Net income (loss) per share
Basic	$ 0.01	$ (0.02)	$ 0.01	$ (0.03)
Diluted	$ 0.01	$ (0.02)	$ 0.01	$ (0.03)

DERIVATIVE LIABILITY (Narrative

DERIVATIVE LIABILITY (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended		18 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	May. 31, 2015	Mar. 31, 2015
DERIVATIVE LIABILITY [Abstract]
Warrant valuation method					Black-Scholes-Merton pricing model
Derivative liability	$ 788,492		$ 788,492		$ 788,492	$ 1,694,651	$ 1,406,596
Change in fair value of derivative liability	$ 1,198,954	$ 644,107	$ 2,312,755	$ 792,364

DERIVATIVE LIABILITY (Valuation

DERIVATIVE LIABILITY (Valuation of Derivative Liabilities) (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May. 31, 2015	Sep. 30, 2015	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Price	$ 0.29	$ 0.10	$ 0.38
Expected volatility		109.32%	76.26%
Expected dividend yield	0.00%	0.00%	0.00%
Fair Value of Derivative Liability	$ 1,694,651	$ 788,492	$ 1,406,596
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 0.45	$ 0.45	$ 0.45
Risk-free interest rate	1.59%	1.31%	1.25%
Expected volatility	107.51%
Expected life (in years)	5 years	4 years 8 months 12 days	4 years 6 months
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 0.35	$ 0.30	$ 0.34
Risk-free interest rate	0.17%	0.08%	0.41%
Expected volatility	76.26%
Expected life (in years)	9 months	4 months 10 days	2 years 6 months

EQUITY (Equity Financing) (Narr

EQUITY (Equity Financing) (Narrative) (Details)	1 Months Ended
	May. 31, 2015USD ($)$ / shares$ / claimshares	Sep. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted		12,900,005
Exercise price of warrants | $ / shares	$ 0.45	$ 0.32	$ 0.41
Warrant expiration period	5 years
Minimum exercise price for automatic reset provision | $ / claim	0.20
Derivative liability | $	$ 1,694,651	$ 788,492	$ 1,406,596
Increase (decrease) to additional paid in capital | $	$ (408,077)
Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	400,000
Exercise price of warrants | $ / shares	$ 0.375
Warrant expiration period	5 years
Securities Purchase Agreement Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock, shares	5,000,002
Shares, Granted	12,500,005
Exercise price of warrants | $ / shares	$ 0.30
Proceeds from issuance of private placement | $	$ 1,500,000
Costs associated with offering | $	208,426
Net proceeds from issuance of private placement | $	$ 1,291,574
Securities Purchase Agreement Warrants, Series One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	5,000,002
Exercise price of warrants | $ / shares	$ 0.45
Warrant expiration period	5 years
Securities Purchase Agreement Warrants, Series One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants | $ / shares		$ 0.20
Securities Purchase Agreement Warrants, Series Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	5,000,002
Exercise price of warrants | $ / shares	$ 0.35
Warrant expiration period	9 months
Securities Purchase Agreement Warrants, Series Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	2,500,001
Exercise price of warrants | $ / shares	$ 0.40
Warrant expiration period	1 year

EQUITY (Common Stock Issued to

EQUITY (Common Stock Issued to Employees and Consultants for Services with Vesting Terms) (Narrative) (Details) - USD ($)	1 Months Ended		6 Months Ended
	Jul. 31, 2015	May. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of shares issued to employees			$ 683,000
Shares vested (value)			93,468	$ 203,680
Fair value of common stock issued for services, shares	310,000	325,000
Fair value of common stock issued for services, amount	$ 61,000	$ 115,000	176,000
Stock-based compensation expense not yet recognized			$ 170,000

EQUITY (Schedule of Non-Vested

EQUITY (Schedule of Non-Vested Restricted Common Stock Activity) (Details) - Restricted Stock [Member]	6 Months Ended
	Sep. 30, 2015shares
Non-vested shares, March 31, 2015	1,833,333
Granted
Vested	(75,000)
Forfeited
Non-vested shares, September 30, 2015	1,758,333

STOCK OPTIONS (Narrative) (Deta

STOCK OPTIONS (Narrative) (Details) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercised during period (shares)
Options exercised during period, exercise price
Stock-based compensation, options vested (value)	$ 149,556	$ 121,721
Unamortized cost of outstanding stock-based awards	$ 300,000
Weighted average remaining vesting period	2 years
Options outstanding, intrinsic value	$ 0	320,500
Intrinsic value of stock options outstanding and exercisable	$ 0	$ 318,500
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period (shares)	1,375,000
Expiration period of options granted	10 years
Expected volatility rate of options granted	76.26%
Expected discount rate of options granted	2.19%
Expected dividend yield of options granted	0.00%
Expected life of options granted	5 years
Options outstanding, intrinsic value	$ 233,000
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period (shares)	1,300,000
Expiration period of options granted	3 years
Expected volatility rate of options granted	109.32%
Expected discount rate of options granted	1.01%
Expected dividend yield of options granted	0.00%
Expected life of options granted	5 years
Options outstanding, intrinsic value	$ 127,000
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	0 months
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted	36 months

STOCK OPTIONS (Schedule of Stoc

STOCK OPTIONS (Schedule of Stock Option Activity) (Details)	6 Months Ended
	Sep. 30, 2015$ / sharesshares
STOCK OPTIONS [Abstract]
Shares, beginning balance outstanding	6,325,000
Shares, Granted	2,675,000
Shares, Exercised
Shares, Cancelled	(8,333)
Shares, ending balance outstanding	8,991,667
Shares, Balance exercisable	6,127,086
Weighted Average Exercise Price, beginning balance outstanding | $ / shares	$ 0.33
Weighted Average Exercise Price, Granted | $ / shares	$ 0.21
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares	$ 0.42
Weighted Average Exercise Price, ending balance outstanding | $ / shares	0.29
Weighted Average Exercise Price, Balance exercisable | $ / shares	$ 0.30

STOCK OPTIONS (Summary of Stock

STOCK OPTIONS (Summary of Stock Options Outstanding) (Details) - $ / shares	6 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	8,991,667	6,325,000
Weighted Average Exercise Price, Options Outstanding	$ 0.29	$ 0.33
Weighted Average Exercise Price, Granted	$ 0.21
Number of Options Exercisable	6,127,086
Weighted Average Exercise Price, Options Exercisable	$ 0.30
Stock Options 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	1,300,000
Weighted Average Exercise Price, Options Outstanding	$ 0.10
Weighted Average Exercise Price, Granted	$ 1
Number of Options Exercisable	1,300,000
Weighted Average Exercise Price, Options Exercisable	$ 0.10
Weighted Average Grant-Date Stock Price, Options Exercisable	$ 1
Stock Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	2,875,000
Number of Options Exercisable	900,000
Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	2,200,000
Number of Options Exercisable	1,491,668
Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	2,016,667
Number of Options Exercisable	1,835,418
Stock Options 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	600,000
Weighted Average Exercise Price, Options Outstanding	$ 0.51
Weighted Average Exercise Price, Granted	$ 0.51
Number of Options Exercisable	600,000
Weighted Average Exercise Price, Options Exercisable	$ 0.51
Weighted Average Grant-Date Stock Price, Options Exercisable	0.51
Minimum [Member] | Stock Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.20
Weighted Average Exercise Price, Granted	0.20
Weighted Average Exercise Price, Options Exercisable	0.20
Weighted Average Grant-Date Stock Price, Options Exercisable	0.20
Minimum [Member] | Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.31
Weighted Average Exercise Price, Granted	0.31
Weighted Average Exercise Price, Options Exercisable	0.31
Weighted Average Grant-Date Stock Price, Options Exercisable	0.31
Minimum [Member] | Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.40
Weighted Average Exercise Price, Granted	0.40
Weighted Average Exercise Price, Options Exercisable	0.40
Weighted Average Grant-Date Stock Price, Options Exercisable	0.40
Maximum [Member] | Stock Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.27
Weighted Average Exercise Price, Granted	0.27
Weighted Average Exercise Price, Options Exercisable	0.27
Weighted Average Grant-Date Stock Price, Options Exercisable	0.27
Maximum [Member] | Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.38
Weighted Average Exercise Price, Granted	0.38
Weighted Average Exercise Price, Options Exercisable	0.38
Weighted Average Grant-Date Stock Price, Options Exercisable	0.38
Maximum [Member] | Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	0.47
Weighted Average Exercise Price, Granted	0.47
Weighted Average Exercise Price, Options Exercisable	0.47
Weighted Average Grant-Date Stock Price, Options Exercisable	$ 0.47

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details) - USD ($)	Aug. 25, 2014	Aug. 25, 2014	May. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.45	$ 0.32		$ 0.32		$ 0.41
Warrant expiration period			5 years
Proceeds from exercise of warrants							$ 1,470,489
Warrants outstanding				25,027,134		25,027,134		12,127,129
Shares, Granted				12,900,005		12,900,005
Cost to induce exercise of warrants					$ 961,767		961,767
Aggregate intrinsic value of all outstanding and exercisable warrants						$ 0	$ 104,000
Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants									$ 0.30
Warrant expiration period				10 years
Shares, Granted									4,400,000
Warrant vesting description						(i) warrants to purchase 800,000 shares of common stock vested immediately at their grant date with a fair value of $201,680, which was recorded as an expense during the year ended March 31, 2015, (ii) warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years with a fair value of $504,204 upon grant date, which is being amortized over their vesting terms, of which $112,045 were recorded as an expense during the six months ended September 30, 2015, and (iii) warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement
Unamortized cost of outstanding warrants				$ 161,000		$ 161,000
Share-based Compensation Award, Tranche One [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	800,000	800,000
Warrant vesting description						vested immediately upon issuance
Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	2,000,000	2,000,000
Share-based Compensation Award, Tranche Three [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	1,600,000	1,600,000
Warrant vesting description						will vest once we achieve certain milestones, including reaching more than $5 million in annual revenue and the planned California stevia extraction and purification facility becoming operational and meeting certain technical performance specifications
Minimum [Member] | Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of warrants	1 year
Maximum [Member] | Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of warrants	3 years
Warrant [Member] | Share-based Compensation Award, Tranche One [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense								$ 201,680
Warrant [Member] | Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants vesting		$ 504,204
Stock-based compensation expense						$ 112,045
Warrant [Member] | Share-based Compensation Award, Tranche Three [Member] | Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted				1,600,000		1,600,000
Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.375
Warrant expiration period			5 years
Shares, Granted			400,000
Securities Purchase Agreement Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock, shares			5,000,002
Exercise price of warrants			$ 0.30
Shares, Granted			12,500,005
Securities Purchase Agreement Warrants, Series One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.45
Warrant expiration period			5 years
Shares, Granted			5,000,002
Securities Purchase Agreement Warrants, Series One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants				$ 0.20		$ 0.20
Securities Purchase Agreement Warrants, Series Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.35
Warrant expiration period			9 months
Shares, Granted			5,000,002
Securities Purchase Agreement Warrants, Series Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.40
Warrant expiration period			1 year
Shares, Granted			2,500,001

WARRANTS (Summary of Warrants t

WARRANTS (Summary of Warrants to Purchase Common Stock Issued) (Details)	6 Months Ended
	Sep. 30, 2015$ / shares$ / claimshares
WARRANTS [Abstract]
Shares, Balance at March 31, 2015	12,127,129
Shares, Granted	12,900,005
Shares, Exercised
Shares, Cancelled
Shares, Balance outstanding and exercisable at September 30, 2015	25,027,134
Weighted Average Exercise Price, Balance at March 31, 2015 | $ / shares	$ 0.41
Weighted Average Exercise Price, Granted | $ / claim	0.34
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price, Balance outstanding and exercisable at September 30, 2015 | $ / shares	$ 0.32

RELATED PARTY TRANSACTIONS AN37

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS (Details) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Aug. 22, 2012	May. 01, 2012
Operating Leased Assets [Line Items]
Operating leases, net rent expense	$ 15,800	$ 30,950
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Lease agreement, expiration date	May 1, 2017
Payments for rent per month	$ 2,300
Security deposit				$ 1,500
Sacramento Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	$ 1,000
Security deposit			$ 1,000

DISTRIBUTION AND LICENSE AGRE38

DISTRIBUTION AND LICENSE AGREEMENTS (Details)	Aug. 16, 2016USD ($)	Aug. 31, 2014shares	Sep. 30, 2015$ / kgshares	Sep. 30, 2015USD ($)$ / kgshares	Sep. 30, 2014USD ($)	Mar. 31, 2015USD ($)	Aug. 25, 2014shares
Shares, Granted			12,900,005	12,900,005
Shares vested aggregate fair value | $				$ 93,468	$ 203,680
Annual revenue milestone | $				$ 5,000,000
Restricted Stock [Member]
Number of warrants or shares vested				75,000
Maximum [Member]
Handling charge, percent of product cost			2.00%
Sales commission charge as percent of product cost			5.00%
Employment Contracts [Member]
Shares, Granted		4,400,000
Warrant vesting terms description				(i) warrants to purchase 800,000 shares of common stock vested immediately at their grant date with a fair value of $201,680, which was recorded as an expense during the year ended March 31, 2015, (ii) warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years with a fair value of $504,204 upon grant date, which is being amortized over their vesting terms, of which $112,045 were recorded as an expense during the six months ended September 30, 2015, and (iii) warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement
Employment Contracts [Member] | Share-based Compensation Award, Tranche One [Member]
Shares, Granted							800,000
Shares vested aggregate fair value | $						$ 321,680
Warrant vesting terms description				vested immediately upon issuance
Employment Contracts [Member] | Share-based Compensation Award, Tranche Two [Member]
Shares, Granted							2,000,000
Employment Contracts [Member] | Share-based Compensation Award, Tranche Three [Member]
Shares, Granted							1,600,000
Warrant vesting terms description				will vest once we achieve certain milestones, including reaching more than $5 million in annual revenue and the planned California stevia extraction and purification facility becoming operational and meeting certain technical performance specifications
Employment Contracts [Member] | Warrant [Member] | Share-based Compensation Award, Tranche One [Member]
Number of warrants or shares vested		800,000
Employment Contracts [Member] | Warrant [Member] | Share-based Compensation Award, Tranche Two [Member]
Number of warrants or shares vested			2,000,000
Employment Contracts [Member] | Warrant [Member] | Share-based Compensation Award, Tranche Three [Member]
Shares, Granted			1,600,000	1,600,000
Employment Contracts [Member] | Restricted Stock [Member]
Stock-based compensation, shares issued during period		2,400,000
Employment Contracts [Member] | Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Number of warrants or shares vested		400,000
Employment Contracts [Member] | Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Number of warrants or shares vested			1,000,000
Employment Contracts [Member] | Restricted Stock [Member] | Share-based Compensation Award, Tranche Three [Member]
Stock-based compensation, shares issued during period			1,000,000
Employment Contracts [Member] | Minimum [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting period of options or warrants granted			1 year
Employment Contracts [Member] | Maximum [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting period of options or warrants granted			3 years
Licensing Agreements [Member] | Scenario, Forecast [Member]
Minimum financing to be obtained pursuant to license agreement | $	$ 2,550,000
Maximum required payments upon completion of milestones | $	$ 700,000
Licensing Agreements [Member] | Minimum [Member]
Royalty payments required pursuant to licensing agreement (dollars per kilogram) | $ / kg			1	1
Licensing Agreements [Member] | Maximum [Member]
Royalty payments required pursuant to licensing agreement (dollars per kilogram) | $ / kg			2	2

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended			6 Months Ended
	Oct. 31, 2015	Jul. 31, 2015	May. 31, 2015	Sep. 30, 2015
Subsequent Event [Line Items]
Fair value of common stock issued for services, shares		310,000	325,000
Fair value of common stock issued for services, amount		$ 61,000	$ 115,000	$ 176,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Fair value of common stock issued for services, shares	263,157
Fair value of common stock issued for services, amount	$ 50,000